Advertisement
LYPHF vs MRK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LYPHF is a Hold and MRK is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LYPHF’s FA Score shows that 0 FA rating(s) are green whileMRK’s FA Score has 2 green FA rating(s).
- LYPHF’s FA Score: 0 green, 5 red.
- MRK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRK’s TA Score shows that 6 TA indicator(s) are bullish.
- MRK’s TA Score: 6 bullish, 2 bearish.
Price Growth
LYPHF (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while MRK (@Pharmaceuticals: Major) price change was +4.36% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.35%. For the same industry, the average monthly price growth was +5.72%, and the average quarterly price growth was +12.95%.
Reported Earning Dates
MRK is expected to report earnings on Oct 30, 2025.
Industries' Descriptions
@Pharmaceuticals: Generic (+6.26% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Pharmaceuticals: Major (+2.35% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| LYPHF | MRK | LYPHF / MRK | |
| Capitalization | 1.86B | 210B | 1% |
| EBITDA | N/A | N/A | - |
| Gain YTD | -22.025 | -13.764 | 160% |
| P/E Ratio | 15.33 | 12.98 | 118% |
| Revenue | N/A | N/A | - |
| Total Cash | N/A | N/A | - |
| Total Debt | N/A | 34.8B | - |
MRK | ||
|---|---|---|
OUTLOOK RATING 1..100 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 71 | |
SMR RATING 1..100 | 24 | |
PRICE GROWTH RATING 1..100 | 56 | |
P/E GROWTH RATING 1..100 | 91 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| LYPHF | MRK | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | N/A | 3 days ago 57% |
| Momentum ODDS (%) | N/A | 3 days ago 49% |
| MACD ODDS (%) | N/A | 3 days ago 51% |
| TrendWeek ODDS (%) | 3 days ago 5% | 3 days ago 49% |
| TrendMonth ODDS (%) | 3 days ago 4% | 3 days ago 46% |
| Advances ODDS (%) | N/A | 3 days ago 47% |
| Declines ODDS (%) | N/A | 18 days ago 51% |
| BollingerBands ODDS (%) | N/A | N/A |
| Aroon ODDS (%) | N/A | 3 days ago 51% |
Advertisement
LYPHF and
Correlation & Price change
A.I.dvisor tells us that LYPHF and MRK have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LYPHF and MRK's prices will move in lockstep.
| Ticker / NAME | Correlation To LYPHF | 1D Price Change % | ||
|---|---|---|---|---|
| LYPHF | 100% | N/A | ||
| MRK - LYPHF | 20% Poorly correlated | +1.75% | ||
| OGN - LYPHF | 13% Poorly correlated | +0.75% | ||
| SNYNF - LYPHF | 2% Poorly correlated | +2.99% | ||
| SCLX - LYPHF | 2% Poorly correlated | +4.09% | ||
| CSWYF - LYPHF | 1% Poorly correlated | N/A | ||
More | ||||
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with PFE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then PFE could also see price increases.